Back to School: How biopharma can reboot drug development. Access exclusive analysis here
KARO will restructure and reduce its headcount by 14 (19%) to 61 to focus its operations. The company said it will continue
Sign in to your BioCentury account to access your content.
Get a two-week free trial subscription to BioCentury